187 related articles for article (PubMed ID: 8768747)
21. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
22. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
Barr AM; Powell SB; Markou A; Geyer MA
Neuropharmacology; 2006 Sep; 51(3):457-65. PubMed ID: 16762376
[TBL] [Abstract][Full Text] [Related]
23. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
24. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone.
Mutlib AE; Strupczewski JT; Chesson SM
Drug Metab Dispos; 1995 Sep; 23(9):951-64. PubMed ID: 8565786
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
[TBL] [Abstract][Full Text] [Related]
26. Biochemical profile of risperidone, a new antipsychotic.
Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
[TBL] [Abstract][Full Text] [Related]
27. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
28. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY
J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793
[TBL] [Abstract][Full Text] [Related]
29. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
30. Effect of local intracerebral administration of EMD 57445, a selective sigma receptor ligand, on the locomotor activity of the rat.
Skuza G; Kolasiewicz W; Dziedzicka-Wasylewska M; Margas W
Pol J Pharmacol; 1998; 50(6):399-406. PubMed ID: 10385922
[TBL] [Abstract][Full Text] [Related]
31. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
32. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
Cook L; Tam SW; Rohrbach KW
J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
[TBL] [Abstract][Full Text] [Related]
33. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
34. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
[TBL] [Abstract][Full Text] [Related]
35. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain.
Cumming P; Ase A; Laliberté C; Kuwabara H; Gjedde A
J Cereb Blood Flow Metab; 1997 Nov; 17(11):1254-60. PubMed ID: 9390657
[TBL] [Abstract][Full Text] [Related]
36. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
38. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
[TBL] [Abstract][Full Text] [Related]
39. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
